Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melphalan/HDS in unresectable hepatocellular carcinoma or intrahepatic cholangiocarcinoma
2014-001585-98Phase 2Terminated
- Sponsor
- Delcath Systems
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of melphalan in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) (2 cohorts), sponsored by Delcath Systems. Primary endpoint: Objective response rate (ORR). Started Apr 2014; status: terminated.
02
Drugs
melphalan
03
Conditions
hepatocellular carcinoma (HCC)intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on 2014-001585-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001585-98.